Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease.
Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME. Lizama BN, et al. Among authors: grundman m. Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22. Neurobiol Dis. 2024. PMID: 38914170 Free article. Clinical Trial.
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, LeVine H 3rd, Grundman M, Caggiano AO, Cirrito JR, Catalano SM, Hamby ME. LaBarbera KM, et al. Among authors: grundman m. Transl Neurodegener. 2023 May 12;12(1):24. doi: 10.1186/s40035-023-00358-w. Transl Neurodegener. 2023. PMID: 37173791 Free PMC article. Clinical Trial. No abstract available.
CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. Lizama BN, et al. Among authors: grundman m. Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21. Alzheimers Dement. 2024. PMID: 39166791 Free PMC article. Clinical Trial.
Antioxidant strategies for Alzheimer's disease.
Grundman M, Grundman M, Delaney P. Grundman M, et al. Proc Nutr Soc. 2002 May;61(2):191-202. doi: 10.1079/PNS2002146. Proc Nutr Soc. 2002. PMID: 12133201 Review.
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Salloway S, et al. Among authors: grundman m. JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937. JAMA Neurol. 2025. PMID: 39556389 Free PMC article. Clinical Trial.
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation.
Cummings J, Gold M, Mintun M, Irizarry M, von Eschenbach A, Hendrix S, Berry D, Sampaio C, Sink K, Landen J, Kivipelto M, Grundman M, Arnold SE, Green A, Partrick K, Nisenbaum L, Burstein A, Fillit H. Cummings J, et al. Among authors: grundman m. J Prev Alzheimers Dis. 2025 Jan;12(1):100001. doi: 10.1016/j.tjpad.2024.100001. Epub 2025 Jan 1. J Prev Alzheimers Dis. 2025. PMID: 39800453 Free article.
138 results